Abstract
Landmark studies by Muller, Mittleman, Tofler and others have suggested that acute myocardial infarctions (MIs) may be triggered by certain phenomena (1–4). It is believed that these triggers, often initiated by an increase in catecholamines and sympathetic nervous system activity, ultimately lead to a disruption of the vulnerable atherosclerotic plaque. Increases in sympathetic vascular tone and sympathetic/catecholamine-related increases in heart rate, blood pressure, ventricular contractility, platelet aggregability, hematocrit, and reductions in fibrinolysis may all contribute (2). For example, an increase in ventricular contractility with changes in dP/dT (change in ventricular pressure over time) and an increase in coronary tone can increase the sheer-stress of blood flowing across a vulnerable atherosclerotic plaque. These mechanical forces may then contribute to rupture of a thin fibrous cap overlying the lipid pool of the plaque. Lipid, foam cells, and tissue factors escape into the lumen of the artery, contributing to platelet aggregation, fibrin deposition, and thrombus, which can then obstruct flow through the coronary artery, causing acute MI and/or sudden death. Reduction in flow also results from an increase in stimulation of alpha sympathomimetic receptors. Increases in heart rate and blood pressure during emotional or physical stress increase oxygen demand, and if O2 supply is limited by coronary stenosis, coronary artery vasospasm, or flow limiting intra-coronary thrombus, ischemia will be worsened.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733–743.
Muller JE, Abela GS, Nesto RW, et al. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994; 23: 809–813.
Muller JE, Mittleman MA, Maclure M, et al. Triggering myocardial infarction by sexual activity. JAMA 1996; 275: 1405–1409.
Muller JE, Kaufmann PG, Luepker RV, et al. Mechanisms precipitating acute cardiac events: review and recommendations of an NHLBI workshop. Circulation 1997; 96: 3233–3239.
Muller JE. Circadian variation in cardiovascular events. Am J Hypertens 1999; 12: 35S - 42S.
Muller JE. Sexual activity as a trigger for cardiovascular events: what is the risk? Am J Cardiol 1999; 84 (Suppl 5B): 2N - 5N.
Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Cardiol 2000; 86 (Suppl): 14F - 18F.
Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999; 99: 2737–2741.
Leor J, Poole WK, Kloner RA. Sudden cardiac death triggered by an earthquake. N Engl J Med 1996; 334: 413–419.
Kloner RA, Poole WK, Perritt RL. When throughout the year is coronary death most likely to occur? A twelve-year population based analysis of over 220,000 cases. Circulation 1999; 100: 1630–1634.
DeBusk R, Drory Y, Goldstein J, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86: 175–181.
Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356–362.
Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1993; 121: 293–298.
Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med 1990; 322: 743–753.
Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy physical exertion. N Engl J Med 1993; 329: 1677–1683.
DeBusk RF. Evaluating the cardiovascular tolerance for sex. Am J Cardiol 2000; 86 (Suppl): 51F - 56F.
Stein RA. Cardiovascular response to sexual activity. Am J Cardiol 2000; 86 (Suppl): 27F - 29F.
Masters WH, Johnson VE. Human Sexual Response. Little, Brown and Co., Boston, 1966.
Hellerstein HK, Friedman EH. Sexual activity in the postcoronary patient. Arch Intern Med 1970; 125: 987–999.
Bohlen JG, Hel JP, Sanderson MO, et al. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med 1984; 144: 1745–1748.
Stein RA. The effect of exercise training on heart rate during coitus in the post myocardial infarction patient. Circulation 1977; 738–740.
Jackson G. Sexual intercourse and angina pectoris. Int. Rehab Med 1981; 3: 35–37.
Jackson G. Sexual intercourse and stable angina pectoris. Am J Cardiol 2000; 86 (Suppl): 35F - 37F.
Namec ED, Mansfield L, Kennedy JW. Heart rate and blood pressure responses during sexual activity in normal males. Am Heart J 1976; 92: 274–277.
Pollock M, Schmidt DH. Heart Disease and Rehabilitation, 3rd ed. Human Kinetics, Champaign, IL, 1995, p. 372.
Larson JL, McNaughton MW, Kennedy JW, et al. Heart rate and blood pressure responses to sexual activity and stair-climbing test. Heart Lung 1980; 9: 1025–1030.
Ueno M. The so-called coition death. Jpn J Legal Med 1969; 17: 333–340.
Drory Y, Shapira I, Fisman EZ, et al. Myocardial ischaemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 835–837.
Moreno PR, Lodder RA, O’Connor WN, et al. Characterization of vulnerable plaques by near infrared spectroscopy in an atherosclerotic rabbit model (abst.). J Am Coll Cardiol 1999; 33 (Suppl A): 66A.
Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates; results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.
Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Preventive Med 2000; 30: 328–338.
Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 400 impotent men. Lancet 1985; 322: 181–184.
Kloner RA, Jarow J. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576–582.
Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86 (Suppl): 57F - 61F.
Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–74.
Kloner RA, Brown M, Prisant LM, et al., for the Sildenafil Study Group. Efficacy and safety of Viagra® (sildenafil citrate) in patients with erectile dysfunction taking concomitant antihypertensive agents. Am J Hypertens 2001; 14: 70–73.
Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83 (Suppl): 29C - 34C.
Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83 (Suppl): 35C - 44C.
Padma-Nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate. Urology 2002; 60 (Suppl 213): 67–90.
Kloner RA, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE5 inhibitor in patients with erectile dysfunction: an analysis of five-controlled clinical trials. Pharmacotherapy 2002; 22: 1371.
Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 2002; 4 (Suppl 14): H32 - H47.
Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331–1334.
Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. A randomized crossover trial. JAMA 2002; 287: 719–725.
Fox KM, Thadani U, Ma PT, et al. Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate (abst). Circulation 2001; 107: 1 1601.
Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006–2012.
Patterson D, MacDonald TM, Effron MB, et al. Tadalafil dose not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation 2002; 106 (Suppl II): II - 330.
Hermann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1662–1666.
Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83 (Suppl 5A): 21C - 28C.
Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA Expert Consensus Document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273–282.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Kloner, R.A. (2004). Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. In: Kloner, R.A. (eds) Heart Disease and Erectile Dysfunction. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-748-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-59259-748-2_15
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9849-3
Online ISBN: 978-1-59259-748-2
eBook Packages: Springer Book Archive